Respiratory syncytial virus risk factors in late preterm infants

References

• Boyce T G, Mellen B G, Mitchel E F, Wright P E, Briffin M R. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000; 137: 865–870
   PubMed Web of Science ®Google Scholar
• Shay D K, Holman R C, Newman R D, Liu L L, Stout J W, Anderson L J. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA 1999; 282: 1440–1446
   PubMed Web of Science ®Google Scholar
• Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 2003; 143: S127–S132
   PubMed Web of Science ®Google Scholar
• Hall C B, Weinberg G A, Iwane M K, Blumkin A K, Edwards K M, Staat M A, Auinger P, Griffin M R, Poehling K A, Erdman D, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360: 588–598
   PubMed Web of Science ®Google Scholar
• Handforth J, Friedland J S, Sharland M. Basic epidemiology and immunopathology of RSV in children. Paediatr Respir Rev 2000; 1: 210–214
   PubMedGoogle Scholar
• Horn S D, Smout R J. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 2003; 143: S133–S141
   PubMed Web of Science ®Google Scholar
• Sampalis J S. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003; 143: S150–S156
   PubMed Web of Science ®Google Scholar
• Simoes E A. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003; 143: S118–S126
   PubMed Web of Science ®Google Scholar
• Welliver R. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr 2003; 143: 112–117
   PubMed Web of Science ®Google Scholar
• Willson D F, Landrigan C P, Horn S D, Smout R J. Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr 2003; 143: S142–S149
   PubMed Web of Science ®Google Scholar
• Italian Institute of Statistics – ISTAT and Italian Ministry of Health. 2005
   Google Scholar
• Carbonell-Estrany X, Figueras-Aloy J. the Infeccio'n Respiratoria Infantil por Virus Respiratorio Sincitial Study Group, Law BJ, the Pediatric Investigators Collaborative Network on Infections in Canada Study Group. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J 2004; 23(11 Suppl)S193–S201
   Google Scholar
• Liese J G, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky B H, Munich RSV Study Group. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003; 162: 230–236
   PubMed Web of Science ®Google Scholar
• Aujard Y, Faroux B. Risk factors for severe respiratory syncytial virus infection in infants. Respir Med 2002; 96(Suppl B)S9–S14
   PubMed Web of Science ®Google Scholar
• Langston C, Kida K, Reed M, Thurlbeck W M. Human lung growth in late gestation and in the neonate. Am Rev Respir Dis 1984; 129: 607–613
   PubMed Web of Science ®Google Scholar
• Hjalmarson O, Sandberg K. Abnormal lung function in healthy preterm infants. Am J Respir Crit Care Med 2002; 165: 83–87
   PubMed Web of Science ®Google Scholar
• Friedrich L, Stein R T, Pitrez P M, Corso A L, Jones M H. Reduced lung function in healthy preterm infants in the first months of life. Am J Respir Crit Care Med 2006; 173: 442–447
   PubMed Web of Science ®Google Scholar
• Handforth J, Friedland J S, Sharland M. Basic epidemiology and immunopathology of RSV in children. Paediatr Respir Rev 2000; 1: 210–214
   PubMedGoogle Scholar
• Yeung C Y, Hobbs J R. Serum-gG-globulin levels in normal, premature, post-mature, and ‘smallfor-dates’ newborn infants. Lancet 1968; 291: 1167–1170
   Google Scholar
• Mussi-Pinhata M M, Gonçlaves A L. Serum immunoglobulin levels and incidence of infection during the first year of life in full-term and preterm infants. J Trop Pediatr 1989; 35: 147–153
   PubMed Web of Science ®Google Scholar
• Ballow M, Cates K L, Rowe J C, Goetz C, Pantschenko A G. Development of the immune system in very low weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections. Pediatr Res 1986; 20: 899–904
   PubMed Web of Science ®Google Scholar
• Law B, Langley J, Allen U, Paes B, Lee D S, Mitchell I, Sampalis J, Walti H, Robinson J, O'Brien K, et al. The pediatric investigators collaborative network on infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004; 23: 806–814
   PubMed Web of Science ®Google Scholar
• Figueras-Aloy J, Carbonell-Estrany X, Quero J, Group IRIS. Case control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain. Pediatr Infect Dis J 2004; 23: 815–820
   PubMed Web of Science ®Google Scholar
• Rossi G A, Medici M C, Arcangeletti M C, Lanari M, Merolla R, Di Luzio Paparatti U, Silvestri M, Pistorio A, Chezzi C, Osservatorio RSV Study Group. Risk factors for severe RSVinduced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr 2007; 166: 1267–1272
   PubMed Web of Science ®Google Scholar
• Meissner H, Welliver R, Chartrand S, Law B, Weisman L, Dorkin H L, Rodriguez W J. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J 1999; 18: 223–231
   PubMed Web of Science ®Google Scholar
• Palivizumab, a humanized Respiratory Syncytial Virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102(3 Part 1)531–537, No authors listed
   Web of Science ®Google Scholar
• American Academy of Pediatrics Redbook. AAP recommendations for RSV Prophylaxis. 2003
   Google Scholar
• Parnes C, Guillermin J, Habersang R, Nicholes P, Chawla V, Kelly T, Fishbein J, McRae P, Goessler M, Gatti A, et al. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol 2003; 35: 484–489
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102: 1211–1216
   PubMed Web of Science ®Google Scholar
• Canadian Paediatric Society (CPS) IDaIC. Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Paediatr Child Health 1999; 4: 474–480
   PubMedGoogle Scholar
• Forster J. Prophylaxis of RSV infections with immunoglobulins. Report of the German Society of Pediatric Infectiology (DGPI). Monatsschrift Kinderheilkunde 1999; 10: 971–972
   Google Scholar
• Azar P, Broglia B, Miceli I NP, Parga L, Castillo E AS, Filho N A, Costa H PF, Kopelman B I, Miranda L EV, Caravajal L FA, et al. Guidelines for the use of palivizumab in the prevention of RSV disease: a consensus opinion. Pediatr Rev (Spanish) 2000; 21: 62–68
   Google Scholar
• SIN. Raccomandazioni della Società Italiana di Neonatologia per la prevenzione delle malattie da virus respiratorio sinciziale (VRS). Acta Neonatol Pediatr 2004; 1: 19–29
   Google Scholar
• American Academy of Pediatrics Redbook. AAP guidelines for RSV immunoprophylaxis. 2009
   Google Scholar
• Simoes EA. Respiratory syncytial virus infection. Lancet 1999; 354: 847–852
   PubMed Web of Science ®Google Scholar
• Karron R A, Singleton R J, Bulkow L, Parkinson A, Kruse D, DeSmet I, Indorf C, Petersen K M, Leombruno D, Hurlburt D, et al. Severe respiratory syncytial virus disease in Alaska native children. RSV Alaska Study Group. J Infect Dis 1999; 180: 41–49
   PubMed Web of Science ®Google Scholar
• Glezen WP, Taber LH, Framk AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986; 140: 543–546
   PubMedGoogle Scholar
• Glezen W P, Paredes A, Allison J E, Taber L H, Frank A L. Risk of respiratory syncytial virus infection for infants from lowincome families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981; 98: 708–715
   PubMed Web of Science ®Google Scholar
• Sim[otilde]es E A, Carbonell-Estrany X, Fullarton J R, Liese J G, Figueras-Aloy J, Doering G, Guzman J. European RSV Risk Factor Study Group. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res 2008; 9: 78
   PubMed Web of Science ®Google Scholar
• Simoes EAF, Carbonell-Estrany X, Fullarton JR, Rossi GA, Lanari M, Barberi I, the European RSV Risk Factor Study Group. European risk factors' model to predict hospitalisation of premature infants born 33–35 weeks' gestational age (wGA) with respiratory syncytial virus (RSV): validation with Italian data. Ped Infect Dis J, Submitted
   Google Scholar